A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)

Published:2022-07-04 Issue:11 Volume:23 Page:1247-1257
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Byun Joo-Young¹²,Park Sun-Kyeong³^ORCID,Ng Boon Peng⁴^ORCID,Liu Yi-Shao¹,Kim Chae-Rin³,Park Chanhyun¹^ORCID

Affiliation:

1. Health Outcomes Division, the University of Texas at Austin, College of Pharmacy, Austin, TX, USA

2. School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

3. College of Pharmacy, the Catholic University of Korea, Bucheon, South Korea

4. College of Nursing & Disability Aging and Technology Cluster, University of Central Florida, Orlando, FL, USA

Funder

Ministry of Health & Welfare, Republic of Korea

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2095203

Reference70 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

3. Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

4. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

5. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

2. Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR;Supportive Care in Cancer;2023-12-27

3. Cabozantinib‐induced edema in zebrafish represents an adverse effect characterized by defects in lymphatic vasculature and renal function;Journal of Biochemical and Molecular Toxicology;2023-06-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3